Four years ago, a potential HIV vaccine showed promise against the virus that causes AIDS, but it fell short of providing the broad protection necessary to stem the spread of disease. Now researchers — led by Duke Medicine — have gained additional insights into the workings of the vaccine that help explain why it benefited a third of recipients and left others vulnerable.